MedTrace Logo

Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation

NCT02194881 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2026-03-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether the treatment with Ivacaftor remains effective and safe in the patients with cystic fibrosis (and at least one G551D CFTR mutation) in the real life setting, after the drug has been approved by the Health authorities.

Conditions

Interventions

DRUG

CF patients with a G551D mutation and treated with Ivacaftor

Sponsors & Collaborators

  • Vaincre la Mucoviscidose

    collaborator OTHER

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Dominique Hubert, MD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-02-29
Completion
2016-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02194881 on ClinicalTrials.gov